Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a plant compound help early Alzheimer's? tiny study begins

NCT ID NCT07279714

Symptom relief Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This pilot study is testing the safety of fisetin, a natural compound found in fruits and vegetables, in 5 older adults with mild Alzheimer's or mild cognitive impairment. Participants will take fisetin daily for a period, and researchers will monitor for side effects. The goal is to see if it is safe enough to study further for possible benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fisetin (a natural plant compound)
What this could lead to
If it works, this could point toward a safe supplement to ease symptoms or slow decline in early Alzheimer's.
What could go wrong
This is a very small pilot study (only 5 people) focused on safety, not effectiveness. It is too early to know if fisetin helps Alzheimer's symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

5 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia * Moca score of 11 or higher * Stable psychotropics and cognitive enhancing medications Exclusion Criteria: * Known hypersensitivity or allergy to fisetin * Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial * Unstable medical disorders * Ongoing treatment for active infection with antibiotics/antifungals * Ongoing treatment for cancer * Active alcohol or substance use disorder * Recent active bleeding * Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin * Use within the last month of other senolytic supplements, antioxidant supplements, natural health products * Other neurologic or neurodegenerative conditions impacting cognition * Active Major Depressive Episode, active suicidal thoughts or psychosis * Any thing that would preclude the ability to undergo an MRI scan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease cognitive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer dementia Alzheimer dementia (AD) Alzheimer disease Alzheimer's disease Mild cognitive disorder Neurocognitive disorder Neurocognitive disorders, mild

Contacts and locations

Locations

  • Sunnybrook Research Institute

    Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.